2026

The Iran-US Conflict and the 2026 Stock Market Outlook: Strategy, Volatility, and Hidden Opportunities
Market News

The Iran-US Conflict and the 2026 Stock Market Outlook: Strategy, Volatility, and Hidden Opportunities

In March 2026, escalating US-Iran tensions have pushed the VIX to the 23-point range, signaling heightened caution but not outright panic. Technical analysis identifies Brent crude above $80 as the primary inflationary trigger monitored by the Fed. Historically, geopolitical shocks result in a median +3% return over 12 months. The current strategy focuses on diplomatic

Palantir (PLTR) 2026: Buying the Hype or Waiting for the Correction?
Strategies

Palantir (PLTR) 2026: Buying the Hype or Waiting for the Correction?

Palantir Technologies (PLTR) remains a cornerstone of the 2026 AI economy, boasting 70% Y/Y revenue growth and an unprecedented 127% Rule of 40 score. Despite its strategic dominance in U.S. Defense and a 137% surge in U.S. Commercial revenue, its 229x P/E ratio signals extreme overvaluation. My thesis suggests capital patience: waiting for the $75–$98

Public Portfolio: Why the Dollar Defied the FUD in February 2026
Trading Portfolio

Public Portfolio: Why the Dollar Defied the FUD in February 2026

In February 2026, my public trading portfolio maintained a +7% YTD return, despite a significant floating drawdown on short positions against the US Dollar (DXY). My core thesis centers on a “DXY Bottom,” driven by decade-low sentiment, AI-led efficiency deflation, and the upcoming Genius Act, targeting a recovery to the 105 level. 1. The Month’s

February 2026 Portfolio Close
Investment Portfolio

February 2026 Portfolio Close: Why I Doubled Down on MSFT, NFLX, and CSU Amidst Market Volatility

In February 2026, my February 2026 Portfolio underwent a strategic consolidation, emphasizing high-growth resilience. I increased positions in Microsoft (MSFT), Netflix (NFLX), and Constellation Software (CSU.TO), leveraging sector-specific volatility. While Bitcoin faced a -28% correction and Novo Nordisk retraced -22%, Netflix led with a +17.2% return. My strategy remains anchored in tiered entries and a

Scroll to Top